Emerging Researchers National (ERN) Conference

nsf-logo[1]

  • About
    • About AAAS
    • About the NSF
    • About the Conference
    • Partners/Supporters
    • Project Team
  • Conference
  • Abstracts
    • Abstract Submission Process
    • Presentation Schedules
    • Abstract Submission Guidelines
    • Presentation Guidelines
    • Undergraduate Abstract Locator (2020)
    • Graduate Abstract Locator (2020)
    • Faculty Abstract Locator (2020)
  • Travel Awards
  • Resources
    • App
    • Award Winners
    • Code of Conduct-AAAS Meetings
    • Code of Conduct-ERN Conference
    • Conference Agenda
    • Conference Materials
    • Conference Program Books
    • ERN Photo Galleries
    • Events | Opportunities
    • Exhibitor Info
    • HBCU-UP/CREST PI/PD Meeting
    • In the News
    • NSF Harassment Policy
    • Plenary Session Videos
    • Professional Development
    • Science Careers Handbook
    • Additional Resources
    • Archives
  • Engage
    • Webinars
    • Video Contest
    • Video Contest Winners
    • ERN 10-Year Anniversary Videos
    • Plenary Session Videos
  • Contact Us

Early Administration of 17- Hydroxyprogesterone Caproate Improves Pathophysiology in RUPP Rats

Undergraduate #122
Discipline: Biological Sciences
Subcategory: Physiology and Health

Jessica McKenzie - Tougaloo College
Co-Author(s): Lorena M. Amaral, Jessica L. Faulkner, Denise C. Cornelius, Janae Moseley, James N. Martin, and Babbette LaMarca, University of Mississippi Medical Center, Jackson, MS



Preeclampsia is characterized by blood pressure greater than 140/90 mmHg after the 20th week of gestation with proteinuria. Preeclampsia also causes increased uterine artery resistance, elevated tumor necrosis factor-α, enhanced of the antiangiogenic factor sFlt-1, and decreased of nitric oxide bioavailability during pregnancy. 17- Hydroxyprogesterone (17OHPC) is already used in prevention of pre-term labor without preeclampsia complications. Therefore, we hypothesized that early administration of 17-hydroxyprogesterone caproate on day 15 of gestation in RUPP rats could improve pathophysiology in response to placental ischemia during pregnancy such as blood pressure (MAP), TNF-α, sFlt-1, UARI, and a increase pup weight and NO bioavailability. Carotid catheters were inserted on day 18 and the uterine artery resistance index was measured using Doppler Ultrasound. Blood pressure, blood and tissues were collected on day 19. MAP in normal pregnant (NP) rats (n=9) was 92 +1.35, 126 +1.98 in RUPP rats (n=17) and 111+1.54 mmHg in RUPP+17-OHPC (n=13), p <0.05. Pup weight was 2.31+0.12 in NP (n=13), 1.88+ 0.05 in RUPP rats (n=24), which improved to 2.01+0.07 grams in RUPP+17-OHPC (n=15), p <0.05. UARI was 0.79+0.03 in RUPP rats (n=4) and 0.59+0.04 in RUPP+17-OHPC(n=5), p<0.05. Plasma levels of TNF-α, sFlt-1 were 64.0+14.1, 385.9+141 in RUPP rats (n=7), which were blunted to 17.8+9.6, 110.2+11.1pg/mL in RUPP+17-OHPC (n=5),p<0.05. Plasma NOx was 10.82+2.3 in RUPP rats (n=13) but was improved to 25.5+5.2 µM in RUPP+17-OHPC (n=5), p<0.05. In conclusion, early administration of 17-OHPC improves inflammation, sFtl-1, Uterine Artery Resistance Index, hypertension, pup weight and nitric oxide bioavailability in response to placental ischemia, and therefore should be considered further for addition to the clinical management of preeclampsia.

Funder Acknowledgement(s): NIH grant RO1HD067541, NIH grant T32HL105324

Faculty Advisor: Babbette LaMarca,

ERN Conference

The 2022 ERN Conference has been postponed.

Full Notice

What’s New

  • Congratulations to Zakiya Wilson-Kennedy on her 2021 AAAS Fellowship
  • Event Vaccination and Liability Policy
  • Webinars
  • Events|Opportunities
  • AAAS CEO Comments on Social Unrest, Racism, and Inequality
  • Maintaining Accessibility in Online Teaching During COVID-19
  • In the News
  • HBCU/CREST PI/PD Meeting

Conference Photos

ERN Conference Photo Galleries

Awards

ERN Conference Award Winners

Checking In

nsf-logo[1]

This material is based upon work supported by the National Science Foundation (NSF) under Grant No. DUE-1930047. Any opinions, findings, interpretations, conclusions or recommendations expressed in this material are those of its authors and do not represent the views of the AAAS Board of Directors, the Council of AAAS, AAAS’ membership or the National Science Foundation.

AAAS

1200 New York Ave, NW Washington,DC 20005
202-326-6400
Contact Us
About Us

The World's Largest General Scientific Society

Useful Links

  • Membership
  • Careers at AAAS
  • Privacy Policy
  • Terms of Use

Focus Areas

  • Science Education
  • Science Diplomacy
  • Public Engagement
  • Careers in STEM

 

  • Shaping Science Policy
  • Advocacy for Evidence
  • R&D Budget Analysis
  • Human Rights, Ethics & Law
© 2022 American Association for the Advancement of Science